HHS recently announced a plan supporting legislation that would allow it to negotiate Medicare Part B and Part D drug prices directly with pharmaceutical companies and then make those prices available to other purchasers, in addition to other key policy proposals to lower medication costs.
In this guest editorial, Rita K. Kuwahara, MD, MIH, a primary care health policy fellow and internal medicine physician at Georgetown University, weighs in on the HHS plan and discusses how affordable drugs would enable providers to shift their focus from reactive care to preventive medicine, which in turn